Related Experiment Videos
Venous thrombosis and rifampicin
1Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa.
Lancet (London, England)
|August 19, 1989
Summary
Rifampicin, an antibiotic for tuberculosis, may increase the risk of deep vein thrombosis (DVT). This study found a higher DVT incidence in patients receiving rifampicin, suggesting preventive measures for inpatients.
Area of Science:
- Medical Research
- Pharmacology
- Public Health
Background:
- Deep vein thrombosis (DVT) is a serious condition often associated with hospitalization.
- Tuberculosis treatment regimens can influence patient outcomes and complication risks.
Purpose of the Study:
- To investigate the association between rifampicin use and the incidence of deep vein thrombosis (DVT) in tuberculosis patients.
- To identify risk factors and temporal patterns of DVT in this patient population.
Main Methods:
- Retrospective analysis of 1366 adult patients admitted to a tuberculosis hospital between 1978 and 1986.
- DVT diagnosis confirmed by contrast venography.
- Comparison of DVT incidence in patients receiving rifampicin-containing regimens versus other treatments.
Main Results:
- Deep vein thrombosis (DVT) complicated 3.4% of admissions.
- Patients treated with rifampicin had a 4.74 times higher relative risk of DVT compared to those on other regimens.
- DVT was more frequent in winter and typically occurred within two weeks of starting treatment.
Conclusions:
- A probable association exists between rifampicin and deep vein thrombosis (DVT).
- Rifampicin use should not be contraindicated solely based on this association.
- Preventive measures against DVT are recommended for inpatients receiving rifampicin.